Home/Pipeline/SLS-007

SLS-007

Parkinson's Disease

PreclinicalResearch

Key Facts

Indication

Parkinson's Disease

Phase

Preclinical

Status

Research

Company

Seelos Therapeutics

About Seelos Therapeutics

Seelos Therapeutics is a publicly traded, clinical-stage biopharmaceutical company focused on the efficient development of therapies for CNS disorders and rare diseases. Founded in 2016, its strategy centers on acquiring and developing a diversified portfolio of assets, including small molecules, psychedelics, and gene therapies, often through repurposing or reformulating known compounds. The company's lead asset, SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB), is in a registration-directed Phase 2 study, representing its most advanced program. Seelos operates as a lean organization, aiming to de-risk development by targeting serious conditions with limited treatment options.

View full company profile

Therapeutic Areas

Central Nervous System (CNS) Disorders Rare Diseases Psychiatry Neurology

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active
golexanolone	Umecrine Cognition	Preclinical	Active